Table 3. Grade ⩾3 adverse events occurred in the study population.
| All sample N=508 | |
|---|---|
| All grade >3 adverse events | |
| Neutropenia | 145 (28.5) |
| Grade ⩾2 neurological toxicity | 131 (25.8) |
| Diarrhoea | 33 (6.5) |
| Asthenia | 16 (3.1) |
| Nausea | 14 (2.8) |
| Vomiting | 11 (2.2) |
| Leukopenia | 11 (2.2) |
| Thrombocytopenia | 6 (1.2) |
| Hepatic toxicity | 6 (1.2) |
| Mucositis | 4 (0.8) |
| Stomatitis | 2 (0.4) |
| Anaemia | 2 (0.4) |
| Skin toxicity | 1 (0.2) |
| First grade ⩾3 FAEs occurred | 194 (38.2) |
| Neutropenia | 130 (67.0) |
| Diarrhoea | 25 (12.9) |
| Leukopenia | 10 (5.2) |
| Asthenia | 8 (4.1) |
| Nausea | 8 (4.1) |
| Thrombocytopenia | 4 (2.1) |
| Mucositis | 4 (2.1) |
| Vomiting | 3 (1.6) |
| Stomatitis | 1 (0.5) |
| Skin toxicity | 1 (0.5) |
Abbreviations: FAEs: fluoropyrimidine-related adverse events.